bluebird bio (BLUE) Stock Forecast, Price & News

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for bluebird bio in the last twelve months. There are currently 2 sell ratings, 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" BLUE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLUE, but not buy additional shares or sell existing shares.
View BLUE analyst ratings or view top-rated stocks.

10 equities research analysts have issued 12 month price targets for bluebird bio's shares. Their BLUE share price forecasts range from $3.00 to $10.00. On average, they predict the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 88.2% from the stock's current price.
View analysts price targets for BLUE or view top-rated stocks among Wall Street analysts.

bluebird bio's stock was trading at $6.92 at the start of the year. Since then, BLUE shares have decreased by 46.2% and is now trading at $3.72.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our BLUE earnings forecast.

bluebird bio, Inc. (NASDAQ:BLUE) announced its earnings results on Tuesday, May, 9th. The biotechnology company reported $0.21 earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.75. The biotechnology company had revenue of $2.40 million for the quarter, compared to analysts' expectations of $26.97 million. bluebird bio had a negative trailing twelve-month return on equity of 52.40% and a negative net margin of 3,054.45%. The business's quarterly revenue was up 26.3% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.66) earnings per share.

ETFs with the largest weight of bluebird bio (NASDAQ:BLUE) stock in their portfolio include SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Products ETF (BBP), Direxion Moonshot Innovators ETF (MOON), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Horizon Kinetics Medical ETF (MEDX), Global X Genomics & Biotechnology ETF (GNOM), Invesco Nasdaq Future Gen 200 ETF (QQQS) and Invesco DWA SmallCap Momentum ETF (DWAS).

91 employees have rated bluebird bio Chief Executive Officer Nick Leschly on Glassdoor.com. Nick Leschly has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other bluebird bio investors own include OPKO Health (OPK), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), NVIDIA (NVDA), Gilead Sciences (GILD), Incyte (INCY), Micron Technology (MU), Alibaba Group (BABA) and (MDVN) (MDVN).

bluebird bio trades on the NASDAQ under the ticker symbol "BLUE."

bluebird bio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include State Street Corp (16.70%), BlackRock Inc. (8.41%), Pictet Asset Management SA (2.92%), Dimensional Fund Advisors LP (2.44%), Geode Capital Management LLC (1.97%) and Bank of America Corp DE (1.85%). Insiders that own company stock include Alison Cecily Finger, Andrew Obenshain, Anne-Virginie Eggimann, David Davidson, Jason Cole, Jessica Whitten, Joanne Smith-Farrell, Katy Burnett, Kory James Wentworth, Nick Leschly, Richard A Colvin, Thomas J Klima and William D Baird III.
View institutional ownership trends.

Shares of BLUE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BLUE stock can currently be purchased for approximately $3.72.

bluebird bio (NASDAQ:BLUE) has a market capitalization of $395.85 million and generates $3.60 million in revenue each year. The biotechnology company earns $-266,580,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis.

The company employs 518 workers across the globe.

bluebird bio's mailing address is 60 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.bluebirdbio.com. The biotechnology company can be reached via phone at (339) 499-9300 or via email at investor@bluebirdbio.com.